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PROMISING OUTCOMES WITH TANDEM AUTOLOGOUS STEM CELL
RESCUE IN ‘LATE’ WILMS TUMOR RELAPSE
Chaudhury, S., Merchant, N., Tse, W., Duerst, R., Schneiderman, J.,
Morgan, E., Kletzel, M. Childrens Memorial Hospital, Northwestern
University’s Feinberg School of Medicine, Chicago, IL
Introduction: Optimal management of relapsed Wilms’ tumor
(WT) patients remains unclear. Modern second-line treatment
consists of either salvage chemotherapy6radiation therapy or
chemotherapy followed by high-dose chemotherapy and autologous
hematopoietic stem cell rescue (HD-ASCR).
Methods:Fifteen consecutive patients with relapsed/ persistentWT
from 2001-09, enrolled on IRB protocol with planned two tandem
cycles of HD-ASCR. Myeloablative chemotherapy regimen for first
cycle consisted of Etoposide 2400 mg/m2, Carboplatin 2000 mg/
m2, Cyclophosphamide 3600 mg/m2; and Melphalan 180 mg/m2
and cyclophosphamide 4500 mg/m2 for the second.
Results: There were 6 males and 9 females with a median age at di-
agnosis of 4.6 y(range 3-16 y), and median time from diagnosis to re-
lapse 1 y (range 0.1- 7.5 y). Median time from relapse to HD-ASCR
was 5m (range 3-31 m). Histology was favorable in 12 and anaplastic
in three. Five of 15 patients received HD-ASCR for early relapse/
refractory disease within 6 months from diagnosis. Ten patients
received planned two cycles of HD-ASCR while the remaining 5 re-
ceived only 1 course of HD-ASCR due to disease progression or tox-
icity. Disease state at the time of HD-ASCRwas CR in 7, VGPR in 5
and PR in 3. Post- ASCR, median time to neutrophil engraftment
and unsupported platelet count .20 K was 12 and 21 days, respec-
tively. Regimen related toxicity included infections (1 aspergillus, 1
klebsiella), hemorrhagic cystitis (1) and one fatal case of acute renal
failure. At a median follow-up of 60 months, nine patients are alive
and disease free. Six patients died from disease relapse in five and re-
nal failure prior to engraftment in one. Five patients with refractory
disease/early relapse (#6 months from initial diagnosis) before un-
dergoing HD-ASCR had significantly worse outcomes from relapse.
(p 5 0.001). The 5 year estimated event-free survival (EFS) and the
overall survival (OS) in the remaining ‘late’ relapsed patients are 55%
and 75% respectively. There was no correlation of outcomewith dis-
ease stage at diagnosis, site of relapse, disease state at ASCR-HD.
Conclusions: Tandem HD-ASCR remains an effective, non-toxic
treatment for patients with relapsed Wilms’ tumor especially
if greater than 6 months from diagnosis. Patients with persistent
disease or early relapse within 6 months from diagnosis likely have
different biological characteristics and should receive a novel modal-
ity of therapy.
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AUTOLOGOUS STEM CELL TRANSPLANT FOR ADVANCED STAGE PEDIAT-
RIC SOLID TUMORS
Hutspardol, S.1, Pakakasama, S.2, Sirachainan, N.2, Anurathapan, U.2,
Hongeng, S.2 1Srinakharinwirot University, Nakorn Nayok, Thailand;
2Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Autologous stem cell transplant (ASCT) potentially promotes the
survival in high-risk pediatric solid tumors. Individual preparative
regimen for each primary solid tumor is not yet determined owing
to various conditions of disease status and previous treatment. We
have transplanted 17 patients with advanced stage solid tumors using
two different preparative regimens. Primary diagnosis included 10
patients (58.9%) with neuroblastoma stage 3 and 4, 2 patients
(11.7%) with Wilms tumor stage 4, 2 patients (11.7%) with germ
cell tumor stage 3 and 4, one each patient with stage 4 rhabdomyo-
sarcoma (5.9%), Ewing’s sarcoma (5.9%), and retinoblastoma
(5.9%). Indication for ASCT was tumor recurrence in 7 patients
(50%) and residual disease in 7 patients (50%). Eleven patients
(65%) with previously treated high-dose cyclophosphamide received
regimen 1 consisting of carboplatin, etoposide, and melphalan dur-
ing conditioning. Regimen 2 (carboplatin, etoposide, cyclophospha-
mide) was chosen for 6 patients (35%) without previous treatment of
high-dose cyclophosphamide. Most patients achieved engraftment
within a median time of 11 days (range 7-18 days). There were 5 pa-tients who alive and disease-free at the end of study. Median follow-
up among survivors was 4.1 years (range 1.2-6.3 years). Disease pro-
gression-free survival (PFS) at 1- and 3-year post-ASCT was 47%
and 32%. Overall survival (OS) at 1-, 3-, and 5-year post-ASCT
was 71%, 36%, and 18%. There was no significant difference in
PFS and OS between two different transplant regimens in univariate
analysis (p 5 0.36 and p 5 0.62). Likewise, there was no significant
difference in PFS andOS between two indications of ASCT (residual
disease and tumor recurrence; p5 0.37 and 0.50), time from diagno-
sis to ASCT (\1 year and$ 1 year; p5 0.72 and 0.24), and primary
diagnosis (neuroblastoma and non-neuroblastoma; p 5 0.75 and
0.87). No severe transplant-related toxicity and mortality was ob-
served herein. Due to limited number of patients in both regimens,
continuing investigation of ASCT role as salvage therapy for ad-
vanced solid tumors should be carried on.
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HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION EN-
HANCES ANTI-TUMOR ACTIVITY AGAINST RENAL CELL CANCER
Budak-Alpdogan, T., Sauter, C., Bailey, C., Biswas, C., Panis, M.,
Civriz, S., Alpdogan, O. Kimmel Cancer Center, Thomas Jefferson Uni-
versity, Philadelphia, PA
AllogeneicHSCThas been suggested as a treatment option for cy-
tokine unresponsive, advanced renal cell cancer (RCC). However,
tumor progression remains as the main problem post-transplant.
We hypothesize that haploidentical (HI)HSCTmight enhance graft
versus tumor (GVT) activity against RCC and improve the outcome
after transplant by tumor growth suppression. We first established
a HI-transplant model using two different hybrid mouse strains as
donor and recipient in the experiments. Lethally irradiated
(CB6F1-(H2Kb/d) recipients were transplanted with T cell-de-
pleted (TCD) bone marrow (BM) from B6CBAF1 (H2Kb/k). We
found that B6CBAF1 TCD-BM cells engrafted well in recipients
of HI-HSCT without graft failure when analyzed at varying time
points after the transplant.
We then exploredGVTactivity in thisHI-HSCTmodel. Lethally
irradiatedCB6F1 host were transplantedTCD-BM from the follow-
ing donors; B6D2F1 (H2Kb/d), B6 (H2Kb), and B6CBAF1 (H2Kb/
k). Animals received RENCA cells on the same day of the transplant.
Low doseT cell (1x105) infusionwas enough to elicit GVT effect but
not GVHD and to provide murine RCC growth control and survival
advantage in HI- HSCT. Recipients of HI-HSCT BM and T cells
showed better anti-tumor activity than recipients of B6D2F1 or B6
BM +TCells, respectively. Recipients of HI-HSCTBM and T cells
did not reveal any tumor development in the first 50 days, and had
a significantly better survival compared to other groups. Low dose
haploidentical CD8+ T cells provided a better anti-tumor activity
than CD4+ T cells but unseparated T cells resulted in significantly
better survival than either subset alone. We concluded from this ex-
periment that GVT activity against to RENCA cells is mainly driven
by CD8+ T cells but they need CD4+ T cells help for optimal anti-
tumor activity.
Our data suggested that HI-HSCT could provide substantial
graft-versus-tumor effect against renal cell carcinoma that might
suppress tumor growth and elicit survival advantage.STEM CELL BIOLOGY461
HUMAN UMBILICAL CORD BLOOD (HUCB) DERIVED STEM CELLS EN-
HANCES WOUND HEALING
Liao, Y.1, Itoh, M.2, Roberts, S.1, Highet, A.M.1, Yang, A.1,
Christiano, A.2, Cairo, M.S.1 1New York Medical College, Valhalla,
NY; 2Columbia University, New York, NY
Background:Recessive dystrophic epidermolysis bullosa (RDEB) is
a severe inherited skin blistering disease caused by mutations in Co-
l7a1gene, which encodes a major component in anchoring fibrils
(Christiano et.al. Nat Gen 1993). An initial report has shown prom-
ises of Allogeneic (Allo) -SCT for the treatment of RDEB (Wagner
et.al.NEngl JMed 2010). However no distinct anchoring fibrils were
observed in the recipient skin and the functional cell populations areS373
S374 Poster Session IIto be characterized. Stem cells with pluripotent properties, including
unrestricted somatic stem cells (USSCs) have been isolated from
HUCB and may represent novel stem cells for the RDEB regenera-
tive therapy (Liao/Cairo et al, Exp. Hem, 2011).
Goal: To determine the potential of USSCs in promoting wound
healing and treating RDEB.
Method: USSCs were isolated from HUCB and characterized by
flow cytometry, RT-PCR, bisulfate sequencing and immunocyto-
chemistry. A 1cm2 full-thickness excisional wound was created at
the dorsal of NSG mice, followed by intradermal injection of 1 mil-
lionUSSCs or PBS at a 1cm- distance from themargin of the wound.
Results: USSCs transcribe a low level of ES factors and have a mo-
saic DNA methylation pattern at the regulatory regions of Nanog
and Oct4. USSCs express Col7a1 at a level that is comparable to hu-
man keratinocytes and fibroblasts. Through an initial treatment of
ascorbic acid, EGF and BMP4 for 7 days followed by culture in de-
fined K-SFMmedium, USSCs were able to differentiate and express
keratinocyte- specific genes. In the mouse wounding model, the
wounds closed at a faster rate in USSC-treated mice as compared
to PBS and a significant difference was observed between the two
groups on days 6-10 post wounding (F(1,168) 5 50.8, P\0.01).
USSCs promoted epithelialization and facilitated formation and re-
modeling of epidermis. More host-derived endothelial cells (PE-
CAM+) were recruited to the USSC-treated wounds as early as
three days post wounding. Furthermore, the USSC-treated skin
healed with skin appendages in the center of the wounded area.
However human cells could be sporadically detected only in the basal
membrane in skin sections without apparent differentiation. This
suggests that the improved murine wound healing is due to a para-
crine effect of USSCs.
Conclusion:HUCB- USSCs showed beneficial effects in cutaneous
regeneration. The ability of USSCs to express Col7A1 and promote
wound healing suggests their potential application in the RDEB
therapy.
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SERINE/THREONINE PIM KINASES PLAY AN IMPORTANT ROLE IN MAIN-
TAINING THE NUMBER AND FUNCTION OF HEMATOPOIETIC STEM CELLS
An, N.1, Lin, Y.-W.2, Liu, A.1, Lilly, M.3, Mahajan, S.1, Kraft, A.1,
Kang, Y.1 1Medical University of South Carolina, Charleston, SC;
2Date Red Cross Hospital, Hokkaido, Japan; 3University of California
Irvine, Irvine, CA
Pim (proviral insertion in murine lymphoma) kinases are a small
family of constitutively active, highly conserved serine/threonine ki-
nases, and have 3 members (Pim1, 2 and 3). The roles of Pim kinases
in the regulation of hematopoietic stem cells (HSCs) are currently
unknown. In the current study, we used transgenic (Tx) and knock-
out (KO) mouse models to characterize the roles of Pim kinases in
hematopoiesis. We generated Pim1 Tx mice bearing human Pim1
kinase under the vav- hematopoietic regulatory elements (vav-
hPim1). Pim1, 2 and 3 single, double and triple KO mice were
also used in this study.We found that: 1). Vav-hPim1Txmice devel-
oped lymphoid, but not myeloid, malignancies. About 10% of vav-
hPim1 Tx mice developed lymphoid leukemia/lymphoma. 2). Vav-
hPim1 Tx mice had increased hematopoietic stem/progenitor cell
(HSPC) population. In those vav-hPim1 Tx mice that were free of
leukemia/lymphoma, a more than 2 fold increase in the number of
c-Kit+Sca-1+Lin- (LSK) HSPCs were noted when compared to
age-matched, wild-type littermates (p less than 0.05). Vav-hPim1
Tx mice exhibited enlarged spleen, higher CXCR4 surface expres-
sion and increased colony forming units (CFUs). Additionally, le-
thally irradiated mice transplanted with splenocytes from vav-
hPIM1 Tx mice had better survival compared to those transplanted
with splenocytes from wild-type control mice. 3). Pim1, 2, 3 single
KO mice had relatively unchanged HSPCs, while Pim1/2, Pim2/3
double KO and Pim1/2/3 triple KO mice exhibited decreased
HSPCs, suggesting potential overlap in function of Pim1, 2, 3 kinase.
When compared to wild-type littermate controls, Pim double or tri-
ple KOmice exhibited lower number of LSKHSPCs, lower CXCR4
surface expression, and reduced CFUs. Furthermore, lethally irradi-
ated mice transplanted with marrow cells from Pim double or triple
KO mice had much slower hematopoietic recovery, compared to
those receiving marrow from normal control mice. 4). IL-3, IL-6
and Thrombopoietin upregulated Pim1 expression in Lin- marrowcells. Stem cell factor and Flt-3 had no effect on Pim 1 expression.
5). Over-expression of Pim1 kinase led to up-regulation of transcrip-
tion factor genes important in the sonic Hedgehog signaling, illus-
trating a potential mechanism through which Pim1 enhances
hematopoiesis. In conclusion, our studies demonstrate a novel role
of Pim serine/threonine kinases in hematopoiesis, and provide
a novel molecular mechanism in the regulation of HSCs.
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ENDOTHELIAL PROGENITOR CELL MOBILIZATION IN C57BL/6 MICE
FOLLOWING TREATMENT WITH SINGLE AGENT OR COMBINATION
NEUPOGEN (G-CSF), PLERIXAFOR (AMD3100), AND VEGF
Frank, R.R.1, Jagan, S.1, Paganessi, L.A.1, McNulty, M.A.2,
Sumner, D.R.2, Fung, H.C.1, Gregory, S.A.1, Christopherson, K.W.1,2
1Rush University Medical Center, Chicago, IL; 2Rush University Medical
Center, Chicago, IL
Introduction: Bone marrow (BM) derived endothelial progenitor
cells (EPC) can differentiate to form vasculature. It is thought that
EPC have a potential role in homeostasis of the endothelium as
well as repair after ischemia or other endothelial injury by inducing
neovasculatization. Successful mobilization of EPC from the BM
into the peripheral blood (PB) would allow for relative ease of collec-
tion and use for cell therapy.
Methods: A screen of 10 agents in C57BL/6mice identifiedG-CSF,
AMD3100, and VEGF as agents that resulted in a$ 2-fold increase
in circulating EPC. Subsequently, neupogen (G-CSF, 50g/kg SC
twice a day for 4 days), plerixafor (AMD3100, 5mg/kg SC, once 1
hr prior), andVEGF (50g/kg SC twice a day for 4 days) were assessed
in individual mice (N5 5) as single agents or in combination. PB and
BM were collected and plated for colony formation at 5%CO2 5%
O2. After 14 days, total EPC and EPC subtypes corresponding to en-
dothelial colony-forming cells (ECFC) and colony-forming units
(CFU-EC), as previously reported by Yoder, et al. Blood 2007,
were scored. In parallel, hematopoietic progenitors (CFU-GM,
BFU-E, & CFU-GEMM) were evaluated after 7 days in culture.
Data is presented as colonies /mL PB or /femur6SEM and analyzed
using Mann-Whitney U test.
Results: Analysis of data indicates, as compared to saline, that treat-
ment with single agent G-CSF, AMD3100, or VEGF results in sig-
nificant mobilization of total EPC into the PB (3.762.1, 61.067.7,
60.463.8, or 37.966.7 CFU/mL respectively, p\0.05). In addition,
the total EPC in the PB increased further with the combination
G-CSF+AMD3100 (95.369.4 CFU/mL, p\0.05) but not
G-CSF+VEGF, VEGF+AMD3100, or G-CSF+VEGF+AMD3100
(65.3615.7, 56.167.7, 54.9618.9 CFU/mL respectively). In all
cases the majority of EPC mobilized into the PB were CFU-EC.
Only AMD3100 mobilized significant numbers of ECFC
(p\0.05). In the BM, total EPC and ECFC decreased in response
to G-CSF but not VEGF or VEGF+AMD3100. G-CSF and
AMD3100 containing regimens but not single agent VEGF mobi-
lized CFU-GM, BFU-E, and CFU-GEMM into the PB (p\0.05).
Conclusion: Treatment with single agent or combination G-CSF,
AMD3100, and VEGF mobilize significant numbers of EPC into
the PB. However, only AMD3100 significantly mobilizes the ECFC
subtype ofEPC that has been reported to formcapillary-like structures
and micro-vessels. Further studies are warranted to assess potential
therapeutic outcomes of mobilized EPC in disease model systems.464
MESENCHYMAL STEM CELLS ENHANCED METASTASIS OF NEUROBLAS-
TOMA VIA SDF-1/CXCR4 AND SDF-1/CXCR7 SIGNALLING
Ma,M., Chan, G.C.-F. The University of Hong Kong, Hong Kong, Hong
Kong
Background&Objective:Bonemarrow is a frequentmetastatic site
for neuroblastoma. The SDF-1/CXCR4 axis has long been proposed
as an important pathway duringmetastasis of various cancers, includ-
ing neuroblastoma (Zhang L, et al. 2007). But the expression and
function of CXCR7, the other known receptor for SDF-1, in meta-
static neuroblastoma has yet to be defined. We investigated the che-
motactic effects of neuroblastma cells towards human bone marrow
mesenchymal stem cells (MSCs) induced by the above two pathways.
